Abstract:Background NT-proBNP-levels are often elevated in patients with atrial fibrillation (AF), but their clinical use and interpretation for predicting subsequent cardiovascular events has not been explored in an all-comers setting. Aim To determine whether NT-proBNP levels are associated with the risk of subsequent heart failure (CHF) and/or death in patients with AF and its relation to prior CHF diagnosis Method All patients with new-onset AF (defined by ICD-code I48) who had an NT-proBNP-level within +/- 14 days of the date of the AF date measured in a regional laboratory repository between 2000-2021 were included in the analysis cohort. Patients were categorized into NT-proBNP level (pg/mL) <1000, 1000-1999, ≥2000. If several NT-proBNP-levels were measured, the maximal value was used. The association between NT-proBNP level and the outcome CHF hospitalization and/or death within 3 years of diagnosis was assessed in Cox regression analyses adjusted for baseline characteristic and medications. Since there was an interaction (p<0.001) between Nt-proBNP-level and prior/new-onset CHF at time of AF diagnosis and no known CHF, two separate analyses were performed in patients with or new-onset CHF and those without prior CHF. Results There were 10559 patients with AF and no CHF, and 11 257 with AF and CHF. There were 14% of patients with new-onset CHF at time of new-onset AF diagnosis. These were grouped together with patients with known CHF. Patients with no prior CHF were younger (76 years (95% CI 68-83) vs 80 (72-87), p<0.001), and healthier with less often diabetes (18.4% vs 24.5%, p<0.001), prior myocardial infarction (12.0% vs 24.3%), a lower CHA2DS2-VASc score (3.0 vs 5.0, p<0.001) and a lower median NT-proBNP level (1650 pg/mL (95% CI 702-3549) vs 4240 pg/mL (2160-8860), p<0.001). Among patients with AF and no prior CHF, the incidence rate in the lowest NT-proBNP level was low, but increased with higher levels (Table). Adjusting for covariates and medications, the risk of both CHF hospitalization and CHF/death compared to the reference category NTproBNP< 1000 pg/mL was nearly 2 and 3 times higher among those who with initial NT-proBNP level 1000-1999 and ≥ 2000. Among patients with AF and known CHF, the incidence rate of CHF hospitalization or CHF hospitalization/death at the same NT-proBNP-strata was several times higher compared to patients without known CHF. Adjusting for covariates, the risk increased for CHF hospitalization or CHF/hospitalization similarly for each strata as for patients without known CHF. AF patients without known HF but with the highest elevation of NTproBNP-level had a risk of subsequent hospitalization of heart failure which was higher than those with known heart failure and lowest NTproBNP-level. Conclusion A higher NTproBNP-level in patients with AF identifies patients at higher risk of CHF hospitalization and/or death in both patients with no and prior CHF.Table

Effect of atrial fibrillation on plasma NT-proBNP in patients with different cardiac functions PAN

Determinants of N-terminal ProBNP Levels in Patients with Atrial Fibrillation and Preserved Left Ventricular Systolic Function

Effects of Percutaneous Balloon Mitral Valvuloplasty on Plasma B-type Natriuretic Peptide in Rheumatic Mitral Stenosis with and Without Atrial Fibrillation.

Corelation Between Plasma N-terminal ProBNP(NT-proBNP) and Cardiac Dysfunction

BNP levels and its influencing factors in patients with acute coronary syndrome

Effect of Bradyarrhythmia on the Plasma Levels of N-terminal Pro-Brain Natriuretic Peptide

Predictive value of NT pro BNP for new‐onset atrial fibrillation in heart failure and preserved ejection fraction

Influence of Atrial Fibrillation Type on Plasma Brain Natriuretic Peptide Level in Male Patients

The association of NT-proBNP levels in atrial fibrillation patients and 3-year risk of heart hospitalization and death

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and Glomerular Filtration Rate in Patients with Acute Heart Failure

NT-proBNP predicts new-onset atrial fibrillation following acute myocardial infarction

Influencing factors for plasma natriuretic peptide and N-terminal pro-B-type natriuretic peptide levels in senior patients with heart failure

Clinical Effects of Recombinant Human BNP in Treating Acute Heart Failure and Study on Its Effects on TWEAK and Nt-Pro BNP

Values of plasma N-terminal pro-B-type natriuretic peptide in severity assessment and prognostic prediction for chronic heart failure in the elderly

Clinical characteristics and outcomes of patients hospitalized with heart failure with preserved ejection fraction and low NT-proBNP levels

Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure

NT-proBNP Levels and Collateral Circulation Status in Patients with Acute Ischemic Stroke

Value Of Serum Nt-Probing Elevation In Predicting Risk Of Atrial Fibrillation In Elderly Male Patients With Normal Heart Function

NTproBNP values for diagnosis of congestive heart failure in old patients regarding atrial fibrillation

B-type natriuretic peptide and platelet parameters change in patients with chronic heart failure

Plasma Brain Natriuretic Peptide Levels in the Diagnosis of Heart Failure